His clinical and research focus is myelodysplastic syndromes and marrow failure disorders. Dr. Steensma has led a number of multicenter trials of hypomethylating agents and hematopoietic growth factors in patients with myelodysplastic syndromes, other myeloid neoplasms, and marrow failure syndromes. He is currently the principal investigator of a study of the first-in-human spliceosome modulator for patients with MDS or AML and mRNA splicing mutations.